BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®
01 oct. 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives Symproic Will be Listed as Preferred Exclusive and BELBUCA Preferred or Preferred Exclusive ...
BioDelivery Sciences Announces Participation in Upcoming Investor Conferences
17 sept. 2019 16h05 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 17, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Announces Upcoming Investor Conference Presentations
29 août 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management
28 août 2019 07h45 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic...
BioDelivery Sciences Reports Strong Second Quarter 2019 Results and Raises Net Sales Expectations
08 août 2019 16h05 HE
|
BioDelivery Sciences International, Inc.
BELBUCA® Net Sales Increased 147% versus Prior Year to All-Time High of $24.1 MillionRaises Full-Year BELBUCA Net Sales Expectations to $90 - $93 MillionRaises Full-Year Total Company Net Sales...
BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
30 juil. 2019 07h45 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions,...
BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA®
09 juil. 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
Regional Commercial Plans Improved Access for More Than 6 Million Lives During 2Q More Than 90% of Commercial Lives Now Have Access to BELBUCA in the U.S. RALEIGH, N.C., July 09, 2019 (GLOBE...
BioDelivery Sciences Expands Upon Report from Pain Management Task Force
24 juin 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically IndicatedHaving Payers Provide Coverage and Reimbursement for...
BioDelivery Sciences Named to the Russell 3000® Index
20 juin 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 20, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is set to be added to the broad-market Russell 3000® Index as well as the Russell 2000® Index...
BioDelivery Sciences Announces Upcoming Investor Conference Presentations
29 mai 2019 16h10 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...